Literature DB >> 26507619

Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress.

Tian-Lin Wang1, Dai-Hong Guo1, Yan Bai1, Ke Wen2, Wen-Yan Han3, Rui Wang4.   

Abstract

BACKGROUND AND OBJECTIVES: Oxidative stress in drug-induced thrombocytopenia (TP) has been discussed. This study was carried out to assess the oxidative stress in patients with normal platelet count (NPC) and TP after linezolid (LZD) treatment and to evaluate if TP caused by LZD is associated with a reduction in antioxidation ability and an increase in lipid peroxidative product in platelets.
METHODS: After LZD treatment for 20 days, 44 patients with TP and 73 patients with NPC were included in this study. Blood samples were collected on the day before medicine treatment and day 7, 14, and 20 after LZD therapy. Levels of reactive oxygen species (ROS), malondialdehyde (MDA), and cholesterol as well as the activities of antioxidative enzyme were estimated. In addition, we identified 37 patients with TP caused by low-dose methotrexate (7.5-25 mg/week) therapy as a positive control group.
RESULTS: In total, 37.60% of cases presented with TP on the 20th day of LZD administration. Individuals with TP had significantly elevated levels of ROS and MDA, low levels of superoxide dismutase (SOD) and catalase (CAT), significantly decreased high-density lipoprotein-cholesterol, low-density lipoprotein (LDL)-cholesterol levels, and increased oxidized-LDL levels in comparison to individuals with NPC. However, no significant changes in the levels of glutathione-peroxidase were found in the course of time. In all cases with LZD, significant increases in levels of ROS, MDA, and ox-LDL were found in the 20-day samples compared with their respective samples before LZD treatment. Correlation analysis revealed a positive association between platelet count and levels of SOD on day 20 and CAT on days 14 and 20 in plasma, a negative association between platelet count and level of MDA and ROS on days 14 and 20 in patients with LZD-induced TP.
CONCLUSIONS: The oxidative stress markers were increased in LZD-induced TP, suggesting that oxidative damage might be the underlying mechanism.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26507619     DOI: 10.1007/s40261-015-0352-0

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  42 in total

1.  Linezolid and reversible myelosuppression.

Authors:  S L Green; J C Maddox; E D Huttenbach
Journal:  JAMA       Date:  2001-03-14       Impact factor: 56.272

2.  Linezolid-related immune-mediated severe thrombocytopenia.

Authors:  Dulce Pascoalinho; Maria João Vilas; Luís Coelho; Pedro Moreira
Journal:  Int J Antimicrob Agents       Date:  2010-11-13       Impact factor: 5.283

Review 3.  New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  E Bouza
Journal:  Clin Microbiol Infect       Date:  2009-12       Impact factor: 8.067

4.  Involvement of NADH/NADPH oxidase in human platelet ROS production.

Authors:  T Seno; N Inoue; D Gao; M Okuda; Y Sumi; K Matsui; S Yamada; K I Hirata; S Kawashima; R Tawa; S Imajoh-Ohmi; H Sakurai; M Yokoyama
Journal:  Thromb Res       Date:  2001-09-01       Impact factor: 3.944

5.  The role of oxidative stress in viral infections.

Authors:  M A Beck; J Handy; O A Levander
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

6.  The role of thiols in protecting against simultaneous toxicity of menadione to platelet plasma and intracellular membranes.

Authors:  Y S Cho; M J Kim; J Y Lee; J H Chung
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

7.  Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

Authors:  Holly A Anger; Felicia Dworkin; Saarika Sharma; Sonal S Munsiff; Diana M Nilsen; Shama D Ahuja
Journal:  J Antimicrob Chemother       Date:  2010-02-11       Impact factor: 5.790

8.  Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6.

Authors:  Brad Spellberg; Thomas Yoo; Arnold S Bayer
Journal:  J Antimicrob Chemother       Date:  2004-08-18       Impact factor: 5.790

Review 9.  Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update.

Authors:  Malini D Coopamah; M Bernadette Garvey; John Freedman; John W Semple
Journal:  Transfus Med Rev       Date:  2003-01

10.  Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report.

Authors:  Filippo Pietrantonio; Maria Di Bartolomeo; Roberto Buzzoni; Emilio Bajetta
Journal:  Tumori       Date:  2010 Jan-Feb
View more
  4 in total

1.  Population Pharmacokinetics and Dosage Optimization of Linezolid in Patients with Liver Dysfunction.

Authors:  Su-Hua Zhang; Zhen-Yu Zhu; Zi Chen; Ying Li; Yang Zou; Miao Yan; Yun Xu; Feng Wang; Mou-Ze Liu; Min Zhang; Bi-Kui Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

2.  Real-Life Frequency of New-Onset Thrombocytopenia during Linezolid Treatment.

Authors:  Nicole Giunio-Zorkin; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2018-04-30

3.  Linezolid vs Vancomycin in Induced Thrombocytopenia.

Authors:  Dimah Al-Harbi; Abdulrahman Alturaiki; Ayshah Alshngeetee; Haya Aldabas; Layla AlBreacan; Renad Aljohani; Eid Hussein Alshahrani; Abdullah Althemery; Laila Carolina Abu Esba
Journal:  Infect Dis Ther       Date:  2022-06-21

Review 4.  Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis.

Authors:  Changcheng Shi; Junbo Xia; Jian Ye; Yaping Xie; Weizhong Jin; Wei Zhang; Liusheng Wang; Xuping Ding; Nengming Lin; Limin Wang
Journal:  Br J Clin Pharmacol       Date:  2021-10-10       Impact factor: 3.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.